Search company, investor...

ClearLight Diagnostics

Founded Year



Series B - II | Alive

Total Raised


Last Raised

$2.77M | 5 yrs ago

About ClearLight Diagnostics

ClearLight Diagnostics is a technology development company focused on the discovery, development, and commercialization of technologies to improve the diagnosis and treatment of a wide range of diseases with an initial focus in oncology.

Headquarters Location

428 Oakmead Parkway

Sunnyvale, California, 94085,

United States


Missing: ClearLight Diagnostics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ClearLight Diagnostics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing ClearLight Diagnostics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ClearLight Diagnostics is included in 5 Expert Collections, including Medical Devices.


Medical Devices

8,537 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Health Monitoring & Diagnostics

2,502 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance


Biopharma Tech

838 items


Health IT

7,901 items

ClearLight Diagnostics Patents

ClearLight Diagnostics has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics



Oncology, Molecular biology, Clusters of differentiation, Transcription factors, Cell biology


Application Date


Grant Date


Related Topics

Oncology, Molecular biology, Clusters of differentiation, Transcription factors, Cell biology



Latest ClearLight Diagnostics News

ClearLight Diagnostics to Present Data on the 3D Imaging of Biomarkers in Core Needle Biopsies of Breast Cancer Patients

Dec 4, 2017

Share this article SUNNYVALE, Calif., Dec. 4, 2017 /PRNewswire/ -- ClearLight Diagnostics, LLC, a developer of an automated next generation tissue processing and 3D imaging platform, announced today that it will present data at the 2017 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas. Poster title: Three-dimensional (3D) Imaging of Biomarkers in Human Core Needle Biopsies of Normal and Cancerous Breast Tissue Authors: Yi Chen, Qi Shen, Laurie J. Goodman, Yesim Gokmen-Polar, Sunil Badve The tumor microenvironment is spatially and compositionally very heterogeneous, which introduces great challenges to characterize when limited to analyzing samples using standard 2D thin section FFPE methods. Capturing high resolution 3D quantitative biomarker data, while simultaneously preserving morphology of the tumor microenvironment, could lead to a better understanding of key spatial relationships and may lead to better prognostic and predictive clinical outcomes. In this study, we utilized a novel technique, CLARITY, to transform core needle biopsies from patients with breast cancer, into optically transparent tissues, followed by multiplexed immunostaining and 3D imaging of molecular markers. This data was compared to the conventional methods of immunohistochemistry and immunofluorescence staining on FFPE thin sections. This is the first study demonstrating that other than fresh or frozen tissues, pre-fixed clinical tissue from patients with breast cancer, can be successfully processed by the CLARITY method and 3D imaged, indicating the potential power of this technique for core needle biopsy tissue processing and the identification of biomarkers based on tumor cell heterogeneity. Abstract #351 Session Title: Tumor cell and molecular biology: Microenvironments-stromal epithelial interaction Program Number: P5-03-02 ClearLight Diagnostics is a technology development company focused on the discovery, development, and commercialization of innovative technologies to significantly improve the diagnosis and treatment of a wide range of diseases with an initial focus in oncology. Founded by Karl Deisseroth M.D., Ph.D., ClearLight is developing an integrated instrumentation platform with the associated optimized biomarker panels based on the CLARITY lipid-clearing technique developed by Dr. Deisseroth and colleagues at Stanford University. This technique enables the transformation of tissue into a nanoporous, hydrogel-hybridized form that is crosslinked to a three-dimensional network of hydrophilic polymers. The process produces a fully assembled, intact tissue, which is permeable to macromolecules and optically transparent, thus allowing for robust three-dimensional imaging of subcellular components (DNA, RNA and protein) and heterogeneous cellular interactions within the tumor microenvironment. This technology, paired with the development of a tissue imaging platform that includes the revolutionary microscopy method, COLM (CLARITY Optimized Light-sheet Microscopy) will enable unprecedented depth and acceleration of image collection from lipid-cleared samples interrogated with biomolecules. Visit us at .

ClearLight Diagnostics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

ClearLight Diagnostics Rank

ClearLight Diagnostics Frequently Asked Questions (FAQ)

  • When was ClearLight Diagnostics founded?

    ClearLight Diagnostics was founded in 2014.

  • Where is ClearLight Diagnostics's headquarters?

    ClearLight Diagnostics's headquarters is located at 428 Oakmead Parkway, Sunnyvale.

  • What is ClearLight Diagnostics's latest funding round?

    ClearLight Diagnostics's latest funding round is Series B - II.

  • How much did ClearLight Diagnostics raise?

    ClearLight Diagnostics raised a total of $8.85M.

  • Who are the investors of ClearLight Diagnostics?

    Investors of ClearLight Diagnostics include Wiegers Capital Partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.